Scientific deep-dive

What People Actually Do After Stopping

Average weight change in the year after stopping was +0.5% for people treated for obesity, and −1.3% for those treated for diabetes. That does not contradict the withdrawal trials. It answers a different question.

By Nora Bissett · Pricing Editor
Editorially reviewed. Not medical advice · How we verify contentLast reviewed
5 min read·2 citations

Everyone knows that stopping a GLP-1 means the weight comes back. A large study of what happened to people who stopped semaglutide or tirzepatide in ordinary care found the average weight change over the following year was 0.5% in people treated for obesity.[1] That is half of one percent, not half of the weight lost. The explanation is not that the trials were wrong.

What the study found

Weight change in people who discontinued semaglutide or tirzepatide in clinical practice.
GroupBaseline to stoppingStopping to one year later
Treated for obesity−8.4% (95% CI −8.7 to −8.1)+0.5% (95% CI 0.0 to 1.0)
Treated for type 2 diabetes−4.4% (95% CI −4.7 to −4.2)−1.3% (95% CI −1.6 to −1.0)

The diabetes group kept losing. The obesity group gained back a fraction of a percent. Neither looks anything like the rebound described in trials of stopping.

Why this does not contradict the trials

In a withdrawal trial, people randomized to placebo receive nothing else. That is the design, and it is what makes it a clean test of the drug. In SURMOUNT-4, people switched to placebo regained about 14% within a year, which we covered in the tirzepatide timeline.

Real patients do not receive nothing. In this study, 19.6% restarted the same medication and 35.2% received an alternative obesity treatment: 27.4% another drug, 13.7% a lifestyle modification visit, and 0.6% metabolic or bariatric surgery.[1]

In the year after stopping, 19.6% restarted the same drug and 35.2% received another obesity treatment. The trial arm that regains everything is the arm where nothing else happens.

So the two findings answer different questions. The trials tell you what the drug was doing. This study tells you what happens to people, in a system where stopping is often a transition rather than an ending.

A second study, and the flaw it shares

An independent 2026 analysis followed 4,182 patients for six months after their last recorded semaglutide or tirzepatide prescription and found much the same thing: roughly two-thirds had stable weight or were still losing.[2] Two datasets reaching the same answer carry more weight than one.

Both studies share a problem, and the second one measured it. A last recorded prescription is not the same event as stopping the drug. The researchers had a language model read the clinical notes for 300 of these patients, and found documented discontinuation for only 119 of them (40%).[2] The other 60% may have switched pharmacy, changed provider, moved to cash-pay or compounded supply, or simply had their next prescription written somewhere the network cannot see.

That matters because someone who quietly kept taking the drug will not regain weight, and will be counted as a success of stopping. It is the single largest reason to hold any “people do fine after stopping” finding loosely.

To the authors’ credit, the sub-analysis answers its own objection as far as it can. Among the 119 whose records confirm they stopped, the pattern held: 72% did not regain weight.[2] That is a much smaller number of people, but it is the number that addresses the question.

The same work made one further observation. Exercise counseling appeared in the notes of 26.2% of those with durable weight loss against 14.7% of those who regained (P = .04).[2] That figure measures what a clinician wrote down, not what a patient did, and documented counseling is a marker of engaged care as much as of exercise. It is consistent with the theme that what happens after stopping matters more than the stopping.

The sentence that limits all of it

The authors write that there was considerable individual-level variability, and that phrase carries more weight than the averages above.[1] A mean change of +0.5% is entirely compatible with a substantial number of people regaining a great deal while others continued to lose.

Averages of this kind describe a population, not a trajectory. If you are deciding whether you can afford to stop, the average is reassuring but tells you very little about your own case, and what you do next appears to matter more than the stopping itself.

Do not read this as permission to stop casually. The authors suggest that restarting or moving to another treatment may be why the average change was so small. A plan for what comes next appears to be doing the work here, and the most common reason people stop, cost, is also the reason they often cannot restart. Our maintenance article covers the alternative of reducing rather than stopping.

What to take from it

  • Stopping is not a cliff for most people, at least not within a year, and the catastrophic framing is overstated. A separate argument holds, though, that the cardiovascular cost may not appear in a weight number at all (see the cardiovascular cost of stopping).
  • What you do next is the variable. Restarting or switching was common and appears to be doing much of the work.
  • Diabetes and obesity are different situations. Those treating diabetes kept losing on average, and the authors put that down to readier access to weight-reducing medication.
  • Your own result may be nothing like the mean. The authors say so explicitly, and it is the most important sentence in the paper.

Frequently Asked Questions

Not on average, in ordinary care. Among people who discontinued semaglutide or tirzepatide, mean weight change over the following year was +0.5% in those treated for obesity and −1.3% in those treated for diabetes, with considerable variation between individuals.
Because in a withdrawal trial the placebo group receives nothing else, which is what makes it a clean test of the drug. In practice, 19.6% of people restarted the same medication and 35.2% received an alternative treatment. The trial arm that regains everything is the arm where nothing else happens.
Enormously. The authors specifically note considerable individual-level variability, which means a mean of +0.5% is compatible with many people regaining substantially while others keep losing. It describes a population rather than predicting a person.
About one in five restarted the same medication. Roughly a third received an alternative obesity treatment: another medication in 27.4% of cases, a lifestyle modification visit in 13.7%, and metabolic or bariatric surgery in 0.6%.
It means the weight consequences at one year are smaller than the popular account, for people who do something else afterward. Whether stopping is advisable is a clinical question, and reducing rather than stopping is a third option with randomized evidence behind it.

References

  1. 1.Gasoyan H, Schulte R, Boyer CB, et al. Obesity Treatments and Weight Changes in Clinical Practice After Discontinuation of Semaglutide or Tirzepatide Diabetes, Obesity and Metabolism. 2026. PMID: 41816857.
  2. 2.Murugadoss K, Varma G, Venkatakrishnan AJ, et al. Weight trajectories after last tirzepatide or semaglutide prescription across a federated health network Biology Methods & Protocols. 2026. PMID: 42163990.

The Cardiovascular Cost of Stopping

A review argues that weight and blood sugar fluctuation are themselves cardiovascular risk factors, and that these drugs do not stabilize arteries the way statins do. It also says few data exist on hard outcomes after stopping.

5 min read

Can You Lower the Dose and Keep the Weight Off?

Stepping down to 5 mg held 16.6% of body weight lost against 21.9% for staying at the full dose. But rescue therapy went from 8% to 25%, and to 67% on placebo.

6 min read

Every Other Week: Stretching the Interval

Patients moved to every-other-week dosing after a plateau held their weight and body composition over 36 weeks. It is a case series with no control group, and it is the third of three different ways to use less drug.

5 min read

Stopping as a Clinical Transition

A review argues discontinuation is a high-risk clinical transition, and reports an association with later heart disease that another review says barely exists as data. Both are describing the same thin literature.

6 min read

Stretching Doses to Save Money

At list prices above a thousand dollars a month, people stretch these drugs. Two papers argue fortnightly dosing keeps most of the weight loss, on a mathematical model and a case series of two patients.

8 min read

Not Taking It and Not Tolerating It

Real-world studies usually measure adherence and stopping separately, with every kind of stopping counted the same way. That merges someone whose body cannot tolerate the drug with someone not taking it reliably. A Scottish study separated them and found different predictors.

6 min read

Where to get GLP-1 online, safely: sellers our editors have checked

These are telehealth sellers our editors have checked. For each one we hold a price, the form the drug comes in, and the states it reaches.

No insurance needed · vetted by our editors

Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more

6.4

MyDrHank

An oral route if you will not self-inject

9.0

YourEra

Semaglutide at $99/month, well below the typical price

8.7

Eden

Coverage in all 50 states, which most sellers will not confirm

About this analysis

GLP Watchdog publishes independently. Each seller in our dataset is checked against that seller's own website, and the dataset is updated continuously. Read our full methodology →